Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-03
1999-12-07
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
059984287
ABSTRACT:
This invention relates to a method for selecting PDE IV inhibitors which have a salutory therapeutic index, and to compounds having these properties.
REFERENCES:
patent: 5278172 (1994-01-01), Hennessey et al.
J. of Pharm and Exp. Therapeutics, (1989), vol. 251, No. 1 Harris et al., Role of Low K.sub.m Cyclic AMP Phosphodiesterase Inhibition in Tracheal relaxation and bronchodiation in the Guinea pig.
Drug Development Research 21:135-142 (1990), Koe et al. Effect of Novel Catechol ether imidazolidinones on Calcium-Independent Phosphodiesterase activity, [.sup.3 H]Rolipram Binding and Reserpine-induced Hypothermia in mice.
Fed. of Eur. Bio. Societies, (1992), vol. 302, No.: 2, 181-184, Souness et al., Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP-specific phosphodiesterase.
P.J. Silver et al., (1990), Low K.sub.m cAMP Phosphodiesterase Isozymes and modulation of Tone in Vascular, Airway and Gastrointestinal Smooth Muscle. pp. 358-365.
Psychopharmacology (1990), 102, 17-20, Schmicchen et al., Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase.
J. Med. Chem. 1991, 34: 291-298, Saccomano et al., Calcium-Independent Phosphodiesterase Inhibitors as Putative Antidepressants: 3-(Bicycloalkyloxy)-4-methoxypheny]-2-imidazolidinones.
J. Med. Chem. 1991, 34, 86-89, Vinick et al., Nicotinamide Ethers: Novel Inhibitors of Calcium-independent Phosphodiesterase and [.sup.3 H]Rolipram Binding.
Br. J. Pharmacol. (1993), 108, 562-568, Cortijo et al., Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
J. Med. Chem, 1993, 36, 1380-1386, Miyamoto et al., Bronchodilator Activity of Xanthine Derivatives Substituted with Functional Groups at the 1- or 7-Position.
J. Med. Chem. vol. 36, No. 22, Oct. 1993 pp. 3274-3277, XP002084976The Crystal structure, absolute config. And phosphodiesterase inhibitory act. Etc . . . P.W. Baures.
Trends Pharmacol. SCI, col. 12, No. 1, 1991 pp. 19-27, XP002012152, Diff. Modulation of tissue function and therapeutic potential etc.. C.D. Nicholson.
Medline. Abstract & Padiatrie Und Genzgebiete, 1991 30 (4) 327-34, Method in individualized pharm. Of diseases of the digestive and the respiratory system in children, XP002084977, M. L. Tarachowski.
Barnette Mary S.
Christensen, IV Siegfried Benjamin
Torphy Theodore J.
Kanagy James M
Kinzig Charles M
MacMillan Keith D.
SmithKline Beecham Corporation
LandOfFree
Compounds and methods for treating PDE IV-related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for treating PDE IV-related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treating PDE IV-related diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-824186